Polarean Imaging plc has named Alan Huang, Ph.D., as vice president of Sales.

Polarean Imaging plc任命Alan Huang博士为销售副总裁。

Dr. Huang has 15 years of experience in the medical device industry, with specific expertise in magnetic resonance imaging (MRI) and MRI-based technologies. He is skilled in executing strategic plans and driving revenue growth of novel technologies. Dr. Huang joins Polarean after nearly 12 years at Philips Healthcare, where he held various roles, most recently as North American Business Leader for the MRI business unit.

黄博士在医疗器械行业拥有15年的经验，在磁共振成像（MRI）和基于MRI的技术方面具有专门知识。他擅长执行战略计划并推动新技术的收入增长。黄博士在飞利浦医疗保健公司（Philips Healthcare）工作了近12年后加入了Polarean，在那里他担任过各种角色，最近一次是MRI业务部门的北美业务负责人。

In this role, he was directly responsible for P&L management and directing the sales and marketing teams. Dr. Huang also developed strategic plans for market growth, supported the reorganization of the commercial organization to sharpen its focus on key markets, and hired channel partners to assist in the management of the business in non-core markets..

。黄博士还制定了市场增长战略计划，支持商业组织的重组，以加强对关键市场的关注，并聘请渠道合作伙伴协助管理非核心市场的业务。。

“I am extremely delighted to welcome Alan to the Polarean team as our vice president of Sales. Having gotten to know him over the past year during our collaboration with Philips, I am confident that he brings a wealth of experience and insights that will greatly complement our current commercial team,' Polarean CEO Christopher von Jako, Ph.D., said. 'This appointment comes at an ideal time following our recent financing, as we aim to expand our sales infrastructure with best-in-class talent to accelerate the adoption of our Xenon MRI technology.

Polarean首席执行官Christopher von Jako博士说：“我非常高兴欢迎Alan作为我们的销售副总裁加入Polarean团队。在过去一年与飞利浦的合作中认识了他，我相信他带来了丰富的经验和见解，这将极大地补充我们目前的商业团队。这一任命是在我们最近融资之后的一个理想时机，因为我们的目标是用一流的人才扩展我们的销售基础设施，以加速氙气MRI技术的采用。

Alan's extensive experience at Philips, where he successfully grew their MR business and built strong relationships with a large number of academic medical centers and clinicians across the US, makes him a tremendous asset to Polarean.”.

Alan在飞利浦拥有丰富的经验，在飞利浦成功发展了MR业务，并与美国各地的大量学术医疗中心和临床医生建立了牢固的关系，这使他成为Polarean的巨大资产。”。

As vice president of Sales, Dr. Huang will be responsible for driving Polarean’s sales strategy and leading the company’s expanding sales team as it accelerates the market adoption of its pulmonary functional Xenon MRI platform technology. He will focus on expanding the technology’s footprint in academic medical centers and driving utilization across the growing install base, enabling improved characterization and management of chronic lung disease for patients and their clinicians..

作为销售副总裁，黄博士将负责推动Polarean的销售战略，并领导公司不断扩大的销售团队，以加速其肺功能氙MRI平台技术的市场采用。他将专注于扩大该技术在学术医疗中心的足迹，并在不断增长的安装基础上提高利用率，从而改善患者及其临床医生对慢性肺病的表征和管理。。

Dr. Huang earned a Ph.D. in biomedical engineering from Johns Hopkins University School of Medicine in Baltimore, Md., and a double bachelor of science degree in neurobiology and electrical and computer engineering from the University of Texas at Austin.

黄博士在马里兰州巴尔的摩的约翰·霍普金斯大学医学院获得生物医学工程博士学位，并在德克萨斯大学奥斯汀分校获得神经生物学、电气和计算机工程双学士学位。

'In my previous roles in diagnostic MRI and Radiation Therapy solutions, I recognized the potential of Polarean’s Xenon MRI technology to significantly improve the characterization and management of chronic lung diseases,' Dr. Huang stated. 'Through the Philips partnership with Polarean and numerous conversations with customers, I became more aware of the significant unmet clinical need and was impressed by the company’s approach.

黄博士说：“在我之前从事MRI诊断和放射治疗解决方案的工作中，我认识到Polarean氙MRI技术在显着改善慢性肺病的表征和管理方面的潜力。”通过飞利浦与Polarean的合作以及与客户的多次对话，我更加意识到临床需求尚未得到满足，并对公司的做法留下了深刻印象。

I am excited to join Polarean and work with the team to expand the reach of Xenon MRI platform technology across the pulmonary clinical community.'.

我很高兴加入Polarean，并与团队合作，将氙MRI平台技术扩展到整个肺部临床社区。”。

Polarean is a revenue-generating medical imaging technology company revolutionizing pulmonary medicine through direct visualization of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function.

Polarean是一家创收的医学成像技术公司，通过将MRI的功能和安全性引入呼吸保健界，通过直接可视化肺功能，彻底改变了肺部医学。。

The company strives to optimize lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarization science and has successfully developed the first and only hyperpolarized Xenon MRI inhaled contrast agent, XENOVIEW, which is now approved by the U.S.

该公司致力于通过揭示隐藏的疾病来优化肺部健康并防止可避免的损失，以满足全球5亿多患有慢性呼吸道疾病的患者的全球未满足的医疗需求。。

Food and Drug Administration. Polarean researches, develops, and commercializes imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarization system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations.

食品和药物管理局。Polarean利用其无创无辐射肺功能MRI平台研究、开发和商业化成像解决方案。该药物设备平台包括专有的氙气混合物，气体超极化系统以及软件和附件，促进了完全集成的现代呼吸成像操作。

Founded in 2012, with offices in Durham, N.C., and London, United Kingdom, Polarean aims to increase global awareness of and broad access to its XENOVIEW MRI technology platform.  .

Polarean成立于2012年，在北卡罗来纳州达勒姆和英国伦敦设有办事处，旨在提高全球对其XENOVIEW MRI技术平台的认识和广泛访问。。